Jan. 30, 2006 — BioTrove and RxGen PrimaTox Inc. will collaborate to provide gene expression and assays designed to work equally well in primates and humans, the companies announced today. The collaborations is expected to bridge the gap between pre-clinical and clinical drug safety analysis.
RxGen PrimaTox, which is in Santa Fe, N.M., will supply gene expression assays that have been designed to work specifically and exclusively on BioTrove’s OpenArray nanofluidic platform. The platform allows simultaneous quantitative analysis of several thousand genes by quantitative PCR. BioTrove is headquartered in Woburn, Mass.